- Home
- PRHI vs CLRB Comparison
PRHI vs CLRB Comparison
Compare PRHI & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRHI | CLRB |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 12.0M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | PRHI | CLRB |
|---|---|---|
| Price | $5.25 | $2.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 28.5K | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.29 |
| 52 Week High | $2.83 | $10.19 |
Technical Indicators
Market Signals| Indicator | PRHI | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 95.42 | 40.67 |
| Support Level | $0.60 | $2.54 |
| Resistance Level | N/A | $3.40 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | 0.31 | -0.03 |
| Stochastic Oscillator | 100.00 | 6.78 |
Price Performance
Historical ComparisonAbout PRHI Presurance Holdings Inc.
Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.